mVISE AG (FRA:C1V)
Germany · Delayed Price · Currency is EUR 0.4760
-0.0200 (-4.03%)
Last updated: Aug 1, 2025
Intra-Cellular Therapies Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 9.33 | 14.18 | 15.64 | 15.98 | 20.24 | Upgrade |
Other Revenue | - | - | 0.2 | - | - | Upgrade |
| 9.33 | 14.18 | 15.84 | 15.98 | 20.24 | Upgrade | |
Revenue Growth (YoY) | -34.21% | -10.46% | -0.84% | -21.08% | -12.97% | Upgrade |
Cost of Revenue | 7.25 | 11.71 | 13.65 | 13.67 | 18.52 | Upgrade |
Gross Profit | 2.08 | 2.48 | 2.2 | 2.31 | 1.73 | Upgrade |
Selling, General & Admin | - | - | - | - | 0.9 | Upgrade |
Other Operating Expenses | 1.97 | 3.75 | 2.61 | 2.13 | 1.93 | Upgrade |
Operating Expenses | 3.84 | 4.5 | 3.1 | 3.33 | 4.63 | Upgrade |
Operating Income | -1.76 | -2.02 | -0.91 | -1.02 | -2.91 | Upgrade |
Interest Expense | -0.37 | -0.38 | -0.38 | -0.48 | -0.32 | Upgrade |
Interest & Investment Income | 0 | 0.1 | 0.01 | 0 | - | Upgrade |
Earnings From Equity Investments | - | - | - | 0.15 | - | Upgrade |
Other Non Operating Income (Expenses) | - | -0.15 | 0 | -0 | - | Upgrade |
EBT Excluding Unusual Items | -2.13 | -2.44 | -1.27 | -1.35 | -3.23 | Upgrade |
Gain (Loss) on Sale of Investments | -0.09 | -0.18 | -0.86 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 1.05 | 0 | Upgrade |
Asset Writedown | - | - | - | -0.02 | -0.03 | Upgrade |
Pretax Income | -2.22 | -2.62 | -2.13 | -0.33 | -3.26 | Upgrade |
Income Tax Expense | 1.76 | 0.8 | 0.09 | -0.02 | 0.85 | Upgrade |
Earnings From Continuing Operations | -3.98 | -3.42 | -2.23 | -0.31 | -4.11 | Upgrade |
Minority Interest in Earnings | - | - | - | 0.01 | 0.12 | Upgrade |
Net Income | -3.98 | -3.42 | -2.23 | -0.3 | -3.99 | Upgrade |
Net Income to Common | -3.98 | -3.42 | -2.23 | -0.3 | -3.99 | Upgrade |
Shares Outstanding (Basic) | 21 | 10 | - | 10 | 9 | Upgrade |
Shares Outstanding (Diluted) | 21 | 10 | - | 10 | 9 | Upgrade |
Shares Change (YoY) | 114.87% | - | - | 10.00% | 0.13% | Upgrade |
EPS (Basic) | -0.19 | -0.35 | - | -0.03 | -0.45 | Upgrade |
EPS (Diluted) | -0.19 | -0.35 | - | -0.03 | -0.45 | Upgrade |
Free Cash Flow | -0.03 | 0.34 | 2.97 | -0.48 | 1.5 | Upgrade |
Free Cash Flow Per Share | -0.00 | 0.04 | - | -0.05 | 0.17 | Upgrade |
Gross Margin | 22.28% | 17.48% | 13.86% | 14.45% | 8.53% | Upgrade |
Operating Margin | -18.85% | -14.21% | -5.71% | -6.40% | -14.36% | Upgrade |
Profit Margin | -42.68% | -24.14% | -14.06% | -1.85% | -19.73% | Upgrade |
Free Cash Flow Margin | -0.31% | 2.43% | 18.77% | -3.00% | 7.39% | Upgrade |
EBITDA | 0.1 | -0.96 | 0.45 | 0.18 | -1.1 | Upgrade |
EBITDA Margin | 1.11% | -6.73% | 2.85% | 1.13% | -5.44% | Upgrade |
D&A For EBITDA | 1.86 | 1.06 | 1.36 | 1.2 | 1.81 | Upgrade |
EBIT | -1.76 | -2.02 | -0.91 | -1.02 | -2.91 | Upgrade |
EBIT Margin | -18.85% | -14.21% | -5.71% | -6.40% | -14.36% | Upgrade |
Advertising Expenses | - | - | - | 0.05 | 0.18 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.